Literature DB >> 15972966

Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations.

Ludovic Lacroix1, Vladimir Lazar, Stefan Michiels, Hugues Ripoche, Philippe Dessen, Monique Talbot, Bernard Caillou, Jean-Pierre Levillain, Martin Schlumberger, Jean-Michel Bidart.   

Abstract

Follicular thyroid carcinomas (FTC) arise through oncogenic pathways distinct from those involved in the papillary histotype. Recently, a t(2;3)(q13;p25) rearrangement, which juxtaposes the thyroid transcription factor PAX8 to the peroxisome proliferator-activated receptor (PPAR) gamma1, was described in FTCs. In this report, we describe gene expression in 11 normal tissues, 4 adenomas, and 8 FTCs, with or without the PAX8-PPARgamma1 translocation, using custom 60-mer oligonucleotide microarrays. Results were confirmed by quantitative real-time polymerase chain reaction of 65 thyroid tissues and by immunohistochemistry. Statistical analysis revealed a pattern of 93 genes discriminating FTCs, with or without the translocation, that were morphologically undistinguishable. Although the expression of thyroid-specific genes was detectable, none appeared to be differentially regulated between tumors with or without the translocation. Differentially expressed genes included genes related to lipid/glucose/amino acid metabolism, tumorigenesis, and angiogenesis. Surprisingly, several PPARgamma target genes were up-regulated in PAX8-PPARgamma-positive FTCs such as angiopoietin-like 4 and aquaporin 7. Moreover many genes involved in PAX8-PPARgamma expression profile presented a putative PPARgamma-promoter site, compatible with a direct activity of the fusion product. These data identify several differentially expressed genes, such as FGD3, that may serve as potential targets of PPARgamma and as members of novel molecular pathways involved in the development of thyroid carcinomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972966      PMCID: PMC1603430          DOI: 10.1016/s0002-9440(10)62967-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  38 in total

1.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected].

Authors:  T G Kroll; P Sarraf; L Pecciarini; C J Chen; E Mueller; B M Spiegelman; J A Fletcher
Journal:  Science       Date:  2000-08-25       Impact factor: 47.728

2.  Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.

Authors:  G Bunone; P Vigneri; L Mariani; S Butó; P Collini; S Pilotti; M A Pierotti; I Bongarzone
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 3.  Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid.

Authors:  James A Fagin
Journal:  Mol Endocrinol       Date:  2002-05

4.  Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM.

Authors:  Mark Aitkenhead; Shur-Jen Wang; Martin N Nakatsu; Javier Mestas; Cheryl Heard; Christopher C W Hughes
Journal:  Microvasc Res       Date:  2002-03       Impact factor: 3.514

5.  Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.

Authors:  K Ohta; T Endo; K Haraguchi; J M Hershman; T Onaya
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

6.  Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation.

Authors:  J C Yoon; T W Chickering; E D Rosen; B Dussault; Y Qin; A Soukas; J M Friedman; W E Holmes; B M Spiegelman
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

7.  Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.

Authors:  Ana Rita Marques; Carla Espadinha; Ana L Catarino; Sónia Moniz; Teresa Pereira; Luís G Sobrinho; Valeriano Leite
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

8.  PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses.

Authors:  Marina N Nikiforova; Paul W Biddinger; Christy M Caudill; Todd G Kroll; Yuri E Nikiforov
Journal:  Am J Surg Pathol       Date:  2002-08       Impact factor: 6.394

9.  The small GTPases Rho and Rac are required for the establishment of cadherin-dependent cell-cell contacts.

Authors:  V M Braga; L M Machesky; A Hall; N A Hotchin
Journal:  J Cell Biol       Date:  1997-06-16       Impact factor: 10.539

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  28 in total

1.  Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma.

Authors:  Melissa E Dobson; Ericka Diallo-Krou; Vladimir Grachtchouk; Jingcheng Yu; Lesley A Colby; John E Wilkinson; Thomas J Giordano; Ronald J Koenig
Journal:  Endocrinology       Date:  2011-09-27       Impact factor: 4.736

2.  The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype.

Authors:  Dang Vu-Phan; Vladimir Grachtchouk; Jingcheng Yu; Lesley A Colby; Max S Wicha; Ronald J Koenig
Journal:  Endocr Relat Cancer       Date:  2013-09-11       Impact factor: 5.678

Review 3.  The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.

Authors:  Jeffrey M Peters; Yatrik M Shah; Frank J Gonzalez
Journal:  Nat Rev Cancer       Date:  2012-02-09       Impact factor: 60.716

4.  Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism.

Authors:  Chunyan Yang; Seung-Hee Jo; Balazs Csernus; Elizabeth Hyjek; Yifang Liu; Amy Chadburn; Y Lynn Wang
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 5.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

Review 6.  Pax-8-PPAR-γ fusion protein in thyroid carcinoma.

Authors:  Priyadarshini Raman; Ronald J Koenig
Journal:  Nat Rev Endocrinol       Date:  2014-07-29       Impact factor: 43.330

7.  MicroRNA expression profiles in differentiated thyroid cancer, a review.

Authors:  Xinying Li; Asim B Abdel-Mageed; Debasis Mondal; Emad Kandil
Journal:  Int J Clin Exp Med       Date:  2012-11-18

8.  Telomere length is related to alternative splice patterns of telomerase in thyroid tumors.

Authors:  Yongchun Wang; Alan K Meeker; Jeanne Kowalski; Hua-Ling Tsai; Helina Somervell; Christopher Heaphy; Lauren E Sangenario; Nijaguna Prasad; William H Westra; Martha A Zeiger; Christopher B Umbricht
Journal:  Am J Pathol       Date:  2011-07-16       Impact factor: 4.307

9.  Molecular detection of PPAR gamma rearrangements and thyroid carcinoma in preoperative fine-needle aspiration biopsies.

Authors:  Christopher A French; Jonathan A Fletcher; Edmund S Cibas; Christopher Caulfield; Paulette Allard; Todd G Kroll
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

10.  Increasing the number of thyroid lesions classes in microarray analysis improves the relevance of diagnostic markers.

Authors:  Jean-Fred Fontaine; Delphine Mirebeau-Prunier; Mahatsangy Raharijaona; Brigitte Franc; Stephane Triau; Patrice Rodien; Olivier Goëau-Brissonniére; Lucie Karayan-Tapon; Marielle Mello; Rémi Houlgatte; Yves Malthiery; Frédérique Savagner
Journal:  PLoS One       Date:  2009-10-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.